Genmab — Juni 2018
-
Ptjaaah, der var jo ikke noget på asco. Måske den info skal bruges ifm forhandlinger efter ema godkendelse?
-
this is in spanish, maybe @bibob can help, Informe de Posicionamiento Terapéutico de daratumumab (Darzalex
) en mieloma múltiple https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-daratumumab-Darzalex-mieloma-multiple-MM.pdf -
and i am just going to repost the article from Plesner from yesterday, as i think most will have missed it , Daratumumab for the Treatment of Multiple Myeloma , https://www.frontiersin.org/articles/10.3389/fimmu.2018.01228/full
-
"If further substantiated that an implication may be that daratumumab should be part of any anti-myeloma treatment. Given the pleiotropic effects of daratumumab, it is in fact difficult to imagine how a myeloma patient can become truly refractory to daratumumab."
-
@EL 10:47 Efter vurderingen af de økonomiske data anses det, at kombination af daratumumab og bortezomib og dexamethason er en værdifuld løsning hos modtagelige patienter, som har erfarne tilbagefald efter i det mindste forudgående behandling, mens kombinationen med lenalidomid og dexamethason ville være en mulighed for situationer, hvor behandling efter et andet tilbagefald.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind